French vaccines developer Valneva’s (Euronext: VLA) shares slumped 39% to 12.14 euros this morning, after it announced that it has received a termination notice from the UK government (HMG) in relation to the supply agreement for its COVID-19 vaccine candidate, VLA2001.
The contract, which was worth up to £1.4 billion ($1.66 bilion), provides the HMG with the right to terminate. The government has alleged that the company is in breach of its obligations under the supply agreement, but Valneva strenuously denies this.
The UK had about 100 million doses on order, after it increased its request by 40 million in February.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze